{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:02:31Z","timestamp":1785333751403,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bbrc.2026.154262","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:17:48Z","timestamp":1783725468000},"page":"154262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A new method to measure serum drug levels to improve the safety of cancer therapies"],"prefix":"10.1016","volume":"830","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5905-6924","authenticated-orcid":false,"given":"Ethan B.","family":"Greenblatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.154262_bib1","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/jamaoncol.2022.4452","article-title":"All optimal dosing roads lead to therapeutic drug monitoring\u2014why take the slow Lane","volume":"8","author":"Beumer","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bbrc.2026.154262_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114315","article-title":"Overview of therapeutic drug monitoring of immunosuppressive drugs: analytical and clinical practices","volume":"205","author":"Seyfinejad","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.bbrc.2026.154262_bib3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/dta.1454","article-title":"Optimization and validation of CEDIA drugs of abuse immunoassay tests in serum and urine on an olympus AU 400","volume":"5","author":"Musshoff","year":"2013","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.bbrc.2026.154262_bib4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1021\/ed066p346","article-title":"Evaluation of EMIT as a qualitative screening test for marijuana use","volume":"66","author":"Rehnstrom","year":"1989","journal-title":"J. Chem. Educ."},{"key":"10.1016\/j.bbrc.2026.154262_bib5","series-title":"Immunoassays for Therapeutic Drug Monitoring and Clinical Toxicology","first-page":"97","author":"Clarke","year":"2020"},{"key":"10.1016\/j.bbrc.2026.154262_bib6","series-title":"Personalized Immunosuppression in Transplantation","first-page":"29","article-title":"Limitations of immunoassays used for therapeutic drug monitoring of immunosuppressants","author":"Dasgupta","year":"2016"},{"key":"10.1016\/j.bbrc.2026.154262_bib7","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1515\/cclm-2022-0984","article-title":"Mass spectrometry in the clinical laboratory. A short journey through the contribution to the scientific literature by CCLM","volume":"61","author":"Rankin-Turner","year":"2023","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.bbrc.2026.154262_bib8","first-page":"272","article-title":"Mass spectrometry applications for toxicology","volume":"27","author":"Mbughuni","year":"2016","journal-title":"EJIFCC"},{"key":"10.1016\/j.bbrc.2026.154262_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1233606","article-title":"Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay","volume":"341","author":"Martinez Molina","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.154262_bib10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41587-019-0388-4","article-title":"Identifying drug targets in tissues and whole blood with thermal-shift profiling","volume":"38","author":"Perrin","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbrc.2026.154262_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev-pharmtox-010715-103715","article-title":"The cellular thermal shift assay: a novel biophysical assay for in situ drug target engagement and mechanistic biomarker studies","volume":"56","author":"Martinez Molina","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bbrc.2026.154262_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s42003-020-0795-6","article-title":"An isothermal shift assay for proteome scale drug-target identification","volume":"3","author":"Ball","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bbrc.2026.154262_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-1-0716-3457-8_5","article-title":"Thermal proteome profiling for drug target identification and probing of protein states","volume":"2718","author":"Sauer","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bbrc.2026.154262_bib14","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1039\/D3MD00145H","article-title":"MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives","volume":"14","author":"Ram","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bbrc.2026.154262_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbrc.2026.154262_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2026.154262_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2026.154262_bib18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s12012-017-9425-z","article-title":"Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism","volume":"17","author":"Banks","year":"2017","journal-title":"Cardiovasc. Toxicol."},{"issue":"28.9.1\u201328.9.14","key":"10.1016\/j.bbrc.2026.154262_bib19","article-title":"Analysis of protein stability and ligand interactions by thermal shift assay","volume":"79","author":"Huynh","year":"2015","journal-title":"Curr. Protoc. Protein Sci."},{"key":"10.1016\/j.bbrc.2026.154262_bib20","doi-asserted-by":"crossref","first-page":"7267","DOI":"10.1021\/jp5030944","article-title":"Temperature induced morphological transitions from native to unfolded aggregated states of human serum albumin","volume":"118","author":"Das","year":"2014","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.bbrc.2026.154262_bib21","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1373\/clinchem.2014.225789","article-title":"Performance of hemoglobin A1c assay methods: good enough?","volume":"60","author":"Little","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bbrc.2026.154262_bib22","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1541-7786.MCR-17-0211","article-title":"BRAF-inhibitor associated MEK mutations increase RAF-dependent and -Independent enzymatic activity","volume":"15","author":"Emery","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154262_bib23","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.0711741105","article-title":"Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity","volume":"105","author":"Tsai","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2026.154262_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194566","article-title":"Monitoring of dabrafenib and trametinib in serum and self-sampled capillary blood in patients with BRAFV600-Mutant melanoma","volume":"14","author":"Isberner","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26010260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26010260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:10:53Z","timestamp":1785330653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26010260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"alternative-id":["S0006291X26010260"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154262","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new method to measure serum drug levels to improve the safety of cancer therapies","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154262","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154262"}}